Thomas Wilder Sells 360 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Thomas Wilder sold 360 shares of the company's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $266.93, for a total transaction of $96,094.80. Following the completion of the transaction, the director now directly owns 4,692 shares in the company, valued at approximately $1,252,435.56. The trade was a 7.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Thomas Wilder also recently made the following trade(s):

• On Monday, March 31st, Thomas Wilder sold 360 shares of Penumbra stock. The stock was sold at an average price of $264.58, for a total value of $95,248.80.

Penumbra Trading Up 1.3 %

Shares of Penumbra stock traded up $3.42 on Wednesday, hitting $259.24. The stock had a trading volume of 167,119 shares, compared to its average volume of 406,683. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00. The stock's 50-day simple moving average is $273.74 and its two-hundred day simple moving average is $246.90. The stock has a market cap of $9.98 billion, a price-to-earnings ratio of 756.07, a PEG ratio of 2.83 and a beta of 0.56.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.09. The business had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. As a group, sell-side analysts predict that Penumbra, Inc. will post 3.67 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PEN shares. Royal Bank of Canada lifted their price target on Penumbra from $285.00 to $313.00 and gave the company an "outperform" rating in a research report on Wednesday, February 19th. Robert W. Baird boosted their price target on shares of Penumbra from $305.00 to $328.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 19th. Citigroup increased their price target on shares of Penumbra from $220.00 to $245.00 and gave the stock a "neutral" rating in a report on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price objective on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Finally, Oppenheimer started coverage on Penumbra in a research note on Tuesday, December 17th. They issued an "outperform" rating and a $275.00 target price on the stock. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Penumbra presently has a consensus rating of "Moderate Buy" and an average target price of $294.47.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Cerity Partners LLC raised its holdings in shares of Penumbra by 19.2% during the third quarter. Cerity Partners LLC now owns 3,612 shares of the company's stock valued at $702,000 after acquiring an additional 583 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Penumbra by 15.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,225 shares of the company's stock worth $1,404,000 after purchasing an additional 953 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Penumbra by 1.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 97,571 shares of the company's stock valued at $18,959,000 after purchasing an additional 995 shares in the last quarter. Edgestream Partners L.P. purchased a new position in shares of Penumbra during the third quarter valued at about $773,000. Finally, Paloma Partners Management Co purchased a new stake in Penumbra in the third quarter worth about $253,000. Hedge funds and other institutional investors own 88.88% of the company's stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.